The aim of this narrative review was to summarize the current knowledge on the role of SGLT2 inhibitors in the treatment of DKD and various physiological, clinical, and genetic factors that may influence the treatment outcomes. This evidence concerns the gene SLC5A2 and diabetic kidney disease.